Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021

Description:

Hypertension is a chronic medical condition characterized by elevated blood pressure in the arteries. It affected an estimated 517 million people in 2014, a figure that will grow at a Compound Annual Growth Rate (CAGR) of 1.2% to 561 million in 2021 in the four Asia-Pacific (APAC) regions of China, India, Australia, and Japan. This high prevalence is a substantial contributor to healthcare costs and a major cause of morbidity. Despite this, awareness of hypertension is low among physicians, patients, and the public alike, leading to poor blood pressure control. Enquiry @ – PowerPoint PPT presentation

Number of Views:57

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Anti-hypertensive Therapeutics in Asia-Pacific Markets to 2021


1
Anti-Hypertensive Therapeutics in Asia-Pacific
Markets to 2021
No. Pages 82
Published on July - 2015
2
.
Report Overview
About Anti-Hypertensive Therapeutics in
Asia-Pacific Markets to 2021 Research Beam added
a report Anti-Hypertensive Therapeutics in
Asia-Pacific Markets to 2021 . Hypertension is a
chronic medical condition characterized by
elevated blood pressure in the arteries. It
affected an estimated 517 million people in 2014,
a figure that will grow at a Compound Annual
Growth Rate (CAGR) of 1.2 to 561 million in 2021
in the four Asia-Pacific (APAC) regions of China,
India, Australia, and Japan. This high prevalence
is a substantial contributor to healthcare costs
and a major cause of morbidity. Despite this,
awareness of hypertension is low among
physicians, patients, and the public alike,
leading to poor blood pressure control. The
classes of drugs prescribed to treat hypertension
are Angiotensin Converting Enzyme Inhibitors
(ACEI), Angiotensin Receptor Blockers (ARB),
Calcium Channel Blockers (CCB), beta-blockers,
renin inhibitors, and diuretics. Get Full
Details On http//www.researchbeam.com/anti-hype
rtensive-therapeutics-in-asia-pacific-to-2021-incr
easing-prevalence-of-hypertension-drives-growth-de
spite-weak-pipeline-market
3
.
Report Overview
  • The percentage of patients treated using
    monotherapy and combination therapy (including
    fixed-dose combinations) varies from country to
    country. The most commonly prescribed drugs in
    the CCB class are amlodipine and lercanidipine,
    while the leading ARBs are telmisartan,
    candesartan, olmesartan, irbesartan, losartan,
    valsartan, azilsartan medoxomil, and eprosartan.
    Ramipril, imidapril, perindopril, enalapril,
    lisinopril, benazepril, fosinopril, trandolapril,
    and quinapril dominate the ACEIs.
  • Scope
  • Hypertension prevalence is a prominent
    contributor to market size in the assessed
    countries. The market is mostly dominated by
    generics, and there are only a few patented
    products.
  • Will generics continue to dominate treatment?-
    How do the elderly populations and their
    associated risk factors affect prevalence?
  • The current anti-hypertensive therapeutics
    pipeline is weak, comprising 124 molecules in
    various stages of development, dominated by small
    molecules.
  • Will the upcoming molecules change the treatment
    paradigm in the near future?
  • How will the weak pipeline affect the market?

4
.
Report Overview
  • Analysis of clinical trials since 2006 identified
    that anti-hypertensive products have a high rate
    of attrition.
  • How do failure rates vary by product stage of
    development, molecule type, and mechanism of
    action?- How do other factors such as average
    trial duration and trial size influence the costs
    and risks associated with product development?
  • Over the 20142021 forecast period, the APAC
    anti-hypertensive therapeutics market is expected
    to increase in value at a CAGR of 3.4 from 15.7
    billion to just over 19.9 billion. Growth is
    projected to vary considerably across the four
    assessed markets.
  • Which markets make the most significant
    contribution to the current market size?
  • What are the epidemiology trends in these
    markets?- Will branded products patent
    expirations pose a significant threat?- Will new
    market entrants over the forecast period lead to
    substantial changes in annual therapy costs?

5
Report Overview
  • Reasons to buy This report will enable you to
  • Understand the clinical context of hypertension
    by considering symptoms, etiology,
    pathophysiology, co-morbidities and
    complications, epidemiology, diagnosis, and
    treatment options.
  • Identify the therapeutic strategies, products,
    and companies that dominate the current marketed
    products landscape, and recognize gaps.-
    Appreciate key anti-hypertensive pipeline trends
    in molecule type, administration route, mechanism
    of action, and novelty.
  • - Consider market opportunities and potential
    risks by examining trends in anti-hypertensive
    clinical trial size, duration, and failure rate
    by stage of development, molecule type, and
    mechanism of action.- Compare treatment usage
    patterns, annual therapy costs, and market growth
    projections for the China, India, Australia, and
    Japan.- Discover trends in licensing and
    co-development deals concerning anti-hypertensive
    products and identify the major strategic
    consolidations that have shaped the commercial
    landscape.

6
Table Of Contents
1 Table of Contents 1 Table of Contents 5 1.1
List of Tables 7 1.2 List of Figures 7 2
Introduction 9 2.1 Pathophysiology 9 2.2 Etiology
10 2.3 Signs and Symptoms 11 2.4 Co-morbidities
and Complications 11 2.5 Diagnosis 13 2.5.1
Office or Clinic Blood Pressure Monitoring
13 2.5.2 Ambulatory Blood Pressure Monitoring
14 2.5.3 Home Blood Pressure Monitoring 14 2.5.4
Miscellaneous Methods 14
7
Table Of Contents
2.5.5 Diagnosis of Target Organ Damage 14 2.5.6
Diagnosis of Hypertension in Pregnancy 15 2.6
Classification 15 2.7 Epidemiology 16 2.8
Prognosis 17 2.9 Treatment and Management
17 2.9.1 Treatment Strategy 19 3 Marketed
Products 26 3.1 Key Marketed Products 26 3.1.1
Prestalia (perindopril arginine amlodipine
besylate) 26 3.1.2 Azilva (azilsartan medoxomil)
26 3.1.3 Amlodipine besylate 26 3.1.4 Telmisartan
27 3.1.5 Aliskiren 28
8
Table Of Contents
3.1.6 Olmesartan medoxomil 29 3.1.7 Valsartan
30 3.1.8 Losartan 31 3.1.9 Exforge (amlodipine
valsartan) 32 3.2 Heat Map for Marketed Products
33 4 Anti-hypertensive Market to 2021 â
Pipeline Products 35 4.1 Overall Pipeline
35 4.1.1 Pipeline Analysis by Molecule Type
36 4.1.2 Pipeline Analysis by Mechanism of Action
37 4.2 Clinical Trial Analysis 39 4.2.1 Failure
Rate 39 Enquiry about this report _at_
http//www.researchbeam.com/anti-hypertensive-ther
apeutics-in-asia-pacific-to-2021-increasing-preval
ence-of-hypertension-drives-growth-despite-weak-pi
peline-market/enquire-about-report
9
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/anti-hypertensive-ther
apeutics-in-asia-pacific-to-2021-increasing-preval
ence-of-hypertension-drives-growth-despite-weak-pi
peline-market
Stay With Us
5933 NE Win Sivers Drive, 205, Portland, OR
97220 United States
TELEPHONE 1 (800) 910-6452 E-MAIL
sales_at_researchbeam.com
About PowerShow.com